Clinical Trial Update: Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP) [Phase 2]

View source ↗

Summary

Open-label Phase 2 extension evaluating the safety and tolerability of multiple-dose regimens of CHF 5074 and exploring potential markers of clinical efficacy i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• CHF 5074

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED